Navigation Links
"Super Drug" Targets Disease-Causing Gene

Researchers at the University of New South Wales in Australia have developed a "super drug" which could one day combat diverse diseases like diabetes//, heart disease, arthritis and cancer. The drug, Dz13, can be used to treat vision loss caused by aging as well, the researchers claimed. Also diseases like heart attacks and inflammation can be contained, they said in a paper published in the latest issue of the journal, Nature Biotechnology. "Our experimental drug Dz13 is like a secret agent that finds its target, c-Jun, within the cell and destroys it," said lead researcher Levon Khachigian, a molecular biologist. The drug works by turning off a disease-causing gene called c-Jun, which is found in diseased blood vessels, eyes, lungs, joints and in the gut. The researchers said animal trials had shown great results. "We're talking about a therapy but whether or not it's a cure remains to be seen," Prof Khachigian said. The drug will be tested at a skin cancer clinical trial next year. Speaking about the research, Professor Bernard Stewart, head of the cancer control program at South Eastern Sydney and Illawarra Health Service said it was a milestone. "It's simple to design drugs on paper that will stop any one of the tens, if not hundreds, of genes that are known to be wrong in cancer," Prof Stewart said. He added that if the drug works in the skin cancer trial, it would be a boon for cancer sufferers, "Conventional chemotherapy works but at a very grim cost in respect of quality of life," Prof Stewart said.
'"/>




Page: 1

Related medicine news :

1. Research Targets treatment for dementia and brain injuries
2. Cancer Treatments Fall Short Of Targets
3. India Targets Eliminating Leprosy
4. Study Would Pave Way for the Development of New Drugs That Targets TB Proteasome
5. Health Targets To Treat Cancer Patients Unlikely To Be Met
6. Queensland Government to Meet its Medical Targets
7. No Clear Evidence for Ultra-Low Cholesterol Targets?
8. Health Minister Stresses the Importance of Realistic Health Targets
9. NIDs Targets Immunizations To 22 Million Children In Bangladesh
10. Researchers Identify New Drug Targets for Cancer
11. VBI Provides Potential Targets to Diabetes Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette ... the Pet Life Radio network. The episode, which was posted this week, features ... what factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association ...
(Date:2/17/2017)... ... 17, 2017 , ... The Alliance Healthcare Foundation (AHF) announced ... positively impact the health and wellness of our community in San Diego and ... to seriously consider releasing our assets beyond our 5% targeted distribution each year ...
(Date:2/17/2017)... VA (PRWEB) , ... February 17, 2017 , ... ... the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 2017  BioDigital, Inc., creators of the BioDigital ... 3D body mapping technology with eClinicalWorks, a privately ... will be used to capture and present dermatology ... human body. BioDigital pilots show using a body ... increasing the precision of clinical annotations compared to ...
(Date:2/17/2017)... -- Noble Capital Markets announced today that it has initiated ... EPIX ). The report was issued by Noble,s Head ... ESSA Pharmaceuticals is a clinical stage biopharmaceutical company ... lead compound EPI-506, is a small molecule oral drug ... receptor, thereby has potential to overcome some of the ...
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
Breaking Medicine Technology: